Prices delayed by at least 15 minutes | Print
Dr Reddy's Laboratories Limited (RDY)
ADS CommonOpen
$70.9
Previous close
$70.91
Trade high
$71.3
Volume
116,990
Year high
$77.72
Year low
$53.12
Dividend yield
0.69%
Market capitalisation
$11.85 bn
P/E ratio
18.94
ISIN
US2561352038
This share can be held in a Dealing accountSIPP
Share price
Dividends
| Previous | Latest | |
|---|---|---|
| Record date | 09/07/2021 | 10/07/2023 |
| Ex-dividend date | 08/07/2021 | 07/07/2023 |
| Payment date | 11/08/2021 | Invalid date |
| Amount | $0.336485 | $0.4876692 |
Company profile
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia(12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over150 APIs and sells in over 75 countries.
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.